Q2 2025 Management View Stacy R. Lindborg, President and CEO, reported unprecedented improvement in overall survival for ...

Imunon, Inc. (($IMNN)) announced an update on their ongoing clinical study. Imunon, Inc. is conducting a Phase 3 clinical trial titled A ...

IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next ...

IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Shares of IMUNON are trading higher Wednesday morning. The company announced a clinical milestone for its lead drug candidate, IMNN-001. The market’s back, and these 3 income stocks are thriving.

LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the ...

IMUNON, Inc. announced a successful Type C Chemistry, Manufacturing, and Controls (CMC) meeting with the FDA, which aligns their production strategy for IMNN-001, a DNA-mediated immunotherapy ...

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer Initiation of additional trial sites and patient enrollment activities ...

IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m 2 administered intraperitoneally weekly) plus neoadjuvant and ...

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on ...

Imunon has been clear about its intent to try to partner the PlaCCine vaccine platform that underpins the COVID-19 candidate since before the phase 1 IMNN-101 trial even started. With six-month ...